Hemoglobinopathies Market Research Report - Global Forecast till 2027

Hemoglobinopathies Market Research Report: Information by Type (Thalassemia (Alpha Thalassemia, Beta Thalassemia), Sickle Cell Disease and other Hb Variant Diseases), Treatment (Stem-cell Transplantation, Blood Transfusions, Analgesics, Antibiotics, ACE inhibitors, Hydroxyurea), End User (Hospitals & Clinics, Diagnostics Laboratories and others) - Global Forecast till 2027

ID: MRFR/HC/6626-HCR | February 2021 | Region: Global | 90 pages

Please note that the assessment period of report has been updated from 2019-2025 to 2020-2027. Cordially fill the sample form for updated data

Market Scenario


Global hemoglobinopathies market is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 5,800 million in 2018 and is projected to register a CAGR of around10.2% over the forecast period.


Hemoglobinopathies is a group of blood disorders such as sickle cell disease, thalassemia, and many others. It is considered the most common inherited disease across the globe. Also, nowadays, hemoglobinopathies have become much more common in central and northern Europe, including Germany, due to immigration.


The rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E is estimated to be the high impact rendering driver of the market. According to the WHO, hemoglobin disorders are endemic in over 60% of the 229 countries affecting over 70% of births. As per the report published by the Centers for Disease Control and Prevention (CDC) in 2015, the initial screening of newborns to identify sickle cell disease (SCD) along with other hemoglobin disorders such as, alpha (α) and beta (β) thalassemia have also gained significant attention in recent years due to the change in the US demographics.


Unhygienic and poor healthcare infrastructure are some of the factors attributing to increase in the base of the target population in low-income regions such as South-East Asia, Mediterranean basin, and African region which will drive the market growth over the forecast period. However, the lack of treatment and diagnosis awareness may hamper the growth of the hemoglobinopathies market during the forecast period.


Segmentation


The global hemoglobinopathies market is segmented based on type, treatment, end users, and region.


The global market for hemoglobinopathies, by type, is segmented into thalassemia, sickle cell disease, and other Hb variants diseases. Thalassemia is further classified as alpha thalassemia and beta thalassemia. Based on treatment, the market is classified into stem-cell transplantation, blood transfusions, analgesics, antibiotics, ACE inhibitors, and hydroxyurea. The market by end user has been classified into hospitals and clinics, diagnostics laboratories, and others. The sickle cell disease segment is expected to hold the largest market share of the hemoglobinopathies market owing to the presence of strong product pipelines such as Lent Globin and rising prevalence of sickle cell disease. Also, based on treatment, the blood transfusion segment holds the largest market share owing to significant success rate and increasing adoption of this treatment option.


In the current scope of the study, the segments mentioned above are covered into four global regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa.


The hemoglobinopathies market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European hemoglobinopathies market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The hemoglobinopathies market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hemoglobinopathies market in the Middle East and Africa has been segmented into the Middle East and Africa.


Key Players



  • Sanofi

  • Sangamo Therapeutics, Inc.

  • Global Blood Therapeutics

  • Neusoft Medical Systems Co., Ltd

  • Bluebird Bio, Inc.

  • Emmaus Life Sciences Inc.

  • Prolong Pharmaceuticals

  • Celgene Corporation

  • Alnylam Pharmaceuticals

  • Gamida Cell

  • Acceleron Pharma

  • Mast Therapeutic

  • HemaQuest Pharmaceuticals

  • Invenux


Regional Market Summary


Global Hemoglobinopathies Market Share (%), by Region, 2017  Hemoglobinopathies Market_Image


Sources: MRFR Analysis


The Americas dominated the global market for hemoglobinopathies owing to the rising geriatric population within the region. As per the data suggested by the American Society of Hematology approximately 70,000 to 100,000 Americans have sickle cell disease, the most common form of an inherited blood disorder.


As per the Centers for Disease Control and Prevention (CDC) in 2010, the US incidence estimate for sickle cell trait (based on information provided by 13 states) was 73.1 cases per 1,000 black newborns, 3.0 cases per 1,000 white newborns, and 2.2 cases per 1,000 Asian or Pacific Islander newborns. The incidence estimates for Hispanic ethnicity (within 13 states) was 6.9 cases per 1,000 Hispanic newborns.


The rising participation of market players is also strongly impacting the growth of the Americas hemoglobinopathies market. For instance, in 2018, in Europe, Sanofi launched the first approved treatment for acquired thrombotic thrombocytopenic purpura (aTTP), bringing a new treatment option to patients who previously had none. In the US, this treatment was approved by the FDA in February 2019.


According to the Centers for Disease Control and Prevention (CDC), SCD affects approximately 100,000 Americans, which occurs among about one out of every 365 black or African American births.


Asia-Pacific (APAC) is expected to represent a phenomenal market growth throughout the forecast period due to the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemia, Hb C, and Hb E.


On the other hand, the Middle East and Africa held the least share in the global hemoglobinopathies market due to the low economic development, especially within the African region.


Market Segmentation


Global Hemoglobinopathies Market, by Type



  • Thalassemia

    • Alpha Thalassemia

    • Beta Thalassemia



  • Sickle Cell Disease

  • Other Hb Variants Diseases


Global Hemoglobinopathies Market, by Treatment



  • Stem-Cell Transplantation

  • Blood Transfusions

  • Analgesics

  • Antibiotics

  • Ace Inhibitors

  • Hydroxyurea


Global Hemoglobinopathies Market, by End User       



  • Hospitals & Clinics

  • Diagnostics Laboratories

  • Others


Global Hemoglobinopathies Market, by Region



  • Americas

    • North America

      • US

      • Canada



    • Latin America





  • Europe

    • Western Europe

      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe



    • Eastern Europe





  • Asia-Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa

    • Middle East

    • Africa




Intended Audience



  • Pharmaceutical companies

  • Government and private laboratories

  • Research and development (R&D) companies

  • Research laboratories

  • Market research and consulting service providers



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 5,800 Million (2025)
  CAGR   10.2% (2019-2025)
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Treatment, End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Sanofi, Sangamo Therapeutics Inc., Global Blood Therapeutics, Bluebird Bio Inc., Emmaus Life Sciences Inc., Prolong Pharmaceuticals, Celgene Corporation, Alnylam Pharmaceuticals, Gamida Cell, Acceleron Pharma, Mast Therapeutic, HemaQuest Pharmaceuticals, and Invenux.
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   The increasing prevalence of hemoglobin-related disorders


Frequently Asked Questions (FAQ) :


global market was valued at USD 5.8 billion in 2018.

Hemoglobinopathies Market is expected to exhibit a strong 10.2% CAGR over the forecast period from 2019 to 2025.

The increasing prevalence of hemoglobin-related disorders is the major driver for the market.

Lack of awareness among consumers and the presence of poor healthcare infrastructure in developing parts of the world are the key restraints on the market.

Leading players in the global hemoglobinopathies market include Sanofi, Emmaus Life Sciences, Gamida Cell, Invenux, Global Blood Therapeutics, Sangamo Therapeutics, Acceleron Pharma, Prolong Pharmaceuticals, and Bluebird Bio Inc., among others.

Table of Contents

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Macroeconomic Indicators

4.5 Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Opportunities

5.4 Pricing Analysis

Chapter 6. Global Hemoglobinopathies Market, By Type

6.1 Introduction

6.2 Thalassemia

6.3.1 Alpha Thalassemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3.2 Beta Thalassemia

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.3 Sickle Cell Disease

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

6.4 Other Hb Variants Diseases

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 7. Global Hemoglobinopathies Market, By Treatment

7.1 Introduction

7.2 Stem-cell transplantation

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.3 Blood transfusions

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.4 Analgesics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.5 Antibiotics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 ACE inhibitors

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

7.6 Hydroxyurea

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 8. Global Hemoglobinopathies Market, By End Users

8.1 Introduction

8.2 Hospitals & Clinics

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.3 Diagnostics Laboratories

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

8.4 Others

Market Estimates & Forecast, by Region, 2020-2027

Market Estimates & Forecast, by Country, 2020-2027

Chapter 9. Global Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 US

9.2.1.2 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia-Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 South Korea

9.4.6 Rest of Asia-Pacific

9.5 Middle East & Africa

9.5.1 Middle East

9.5.2 Africa

Chapter 10. Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

Chapter 11. Company Profiles

11.1 Sanofi

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials Overview

11.1.4 Key Developments

11.1.5 SWOT Analysis

11.2 Sangamo Therapeutics Inc.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Global Blood Therapeutics

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 bluebird bio Inc

11.4.1 Company Overview

11.4.2 Product Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Emmaus Life Sciences Inc.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 Prolong Pharmaceuticals

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Celgene Corporation

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Alnylam Pharmaceuticals

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Gamida Cell

11.9.1 Overview

11.9.2 Product Overview

11.9.3 Financials

11.9.4 Key Developments

11.9.5 SWOT Analysis

11.10 Acceleron Pharma

11.10.1 Overview

11.10.2 Product Overview

11.10.3 Financials

11.10.4 Key Developments

11.10.5 SWOT Analysis

11.11 Mast Therapeutic

11.11.1 Overview

11.11.2 Product Overview

11.11.3 Financials

11.11.4 Key Developments

11.11.5 SWOT Analysis

11.12 HemaQuest Pharmaceuticals

11.12.1 Overview

11.12.2 Product Overview

11.12.3 Financials

11.12.4 Key Developments

11.12.5 SWOT Analysis

11.13 Invenux

11.13.1 Overview

11.13.2 Product Overview

11.13.3 Financials

11.13.4 Key Developments

11.13.5 SWOT Analysis

11.14 Other

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s Viewpoint

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Predictions for the Global Hemoglobinopathies Market

Chapter 13 Appendix

LIST OF TABLES

Table 1 Hemoglobinopathies Market Synopsis, 2020-2027

Table 2 Hemoglobinopathies Market Estimates and Forecast, 2020-2027(USD Million)

Table 3 Global Hemoglobinopathies Market, by Region, 2020-2027(USD Million)

Table 4 Global Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 5 Global Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 6 Global Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 7 North America: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 8 North America: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 9 North America: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 10 US: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 11 US: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 12 US: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 13 Canada: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 14 Canada: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 15 Canada: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 16 South America: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 17 South America: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 18 South America: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 19 Europe: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 20 Europe: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 21 Europe: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 22 Western Europe: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 23 Western Europe: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 24 Western Europe: Hemoglobinopathies Market, by End User, 2020-2027(USD Million)

Table 25 Eastern Europe: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 26 Eastern Europe: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 27 Eastern Europe: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 28 Asia-Pacific: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 29 Asia-Pacific: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 30 Asia-Pacific: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

Table 31 Middle East & Africa: Hemoglobinopathies Market, by Type, 2020-2027(USD Million)

Table 32 Middle East & Africa: Hemoglobinopathies Market, by Treatment, 2020-2027(USD Million)

Table 33 Middle East & Africa: Hemoglobinopathies Market, End User, 2020-2027(USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Hemoglobinopathies Market

Figure 3 Market Dynamics for Global Hemoglobinopathies Market

Figure 4 Hemoglobinopathies Market Share, by Type, 2020

Figure 5 Hemoglobinopathies Market Share, by Treatment, 2020

Figure 6 Hemoglobinopathies Market Share, End User, 2020

Figure 7 Hemoglobinopathies Market Share, by Region, 2020

Figure 8 North America: Hemoglobinopathies Market Share, by Country, 2020

Figure 9 Europe: Hemoglobinopathies Market Share, by Country, 2020

Figure 10 Asia-Pacific: Hemoglobinopathies Market Share, by Country, 2020

Figure 11 Middle East & Africa: Hemoglobinopathies Market Share, by Region, 2020

Figure 12 Hemoglobinopathies Market: Company Share Analysis, 2020 (%)

Figure 13 Sanofi: Key Financials

Figure 14 Sanofi: Segmental Revenue

Figure 15 Sanofi: Geographical Revenue

Figure 16 Sangamo Therapeutics Inc.: Key Financials

Figure 17 Sangamo Therapeutics Inc.: Segmental Revenue

Figure 18 Sangamo Therapeutics Inc.: Geographical Revenue

Figure 19 Global Blood Therapeutics: Key Financials

Figure 20 Global Blood Therapeutics: Segmental Revenue

Figure 21 Global Blood Therapeutics: Geographical Revenue

Figure 22 bluebird bio Inc: Key Financials

Figure 23 bluebird bio Inc: Segmental Revenue

Figure 24 bluebird bio Inc: Geographical Revenue

Figure 25 Emmaus Life Sciences Inc.: Key Financials

Figure 26 Emmaus Life Sciences Inc.: Segmental Revenue

Figure 27 Emmaus Life Sciences Inc.: Geographical Revenue

Figure 28 Prolong Pharmaceuticals: Key Financials

Figure 29 Prolong Pharmaceuticals: Segmental Revenue

Figure 30 Prolong Pharmaceuticals: Geographical Revenue

Figure 31 Celgene Corporation: Key Financials

Figure 32 Celgene Corporation: Segmental Revenue

Figure 33 Celgene Corporation: Geographical Revenue

Figure 34 Alnylam Pharmaceuticals: Key Financials

Figure 35 Alnylam Pharmaceuticals: Segmental Revenue

Figure 36 Alnylam Pharmaceuticals: Geographical Revenue

Figure 37 Gamida Cell: Key Financials

Figure 38 Gamida Cell: Segmental Revenue

Figure 39 Gamida Cell: Geographical Revenue

Figure 40 Acceleron Pharma: Key Financials

Figure 41 Acceleron Pharma: Segmental Revenue

Figure 42 Acceleron Pharma: Geographical Revenue

Figure 43 Mast Therapeutic: Key Financials

Figure 44 Mast Therapeutic: Segmental Revenue

Figure 45 Mast Therapeutic: Geographical Revenue

Figure 46 HemaQuest Pharmaceuticals: Key Financials

Figure 47 HemaQuest Pharmaceuticals: Segmental Revenue

Figure 48 HemaQuest Pharmaceuticals: Geographical Revenue




This table of content is tentative and subject to change as the research progresses.

Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.